Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry
Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness. Study Design: Prospective observational registry enrolling those who received...
Gespeichert in:
| Veröffentlicht in: | Journal of Perinatology 2008-07, Vol.28 (7), p.511-517 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 517 |
|---|---|
| container_issue | 7 |
| container_start_page | 511 |
| container_title | Journal of Perinatology |
| container_volume | 28 |
| creator | Frogel, M Nerwen, C Cohen, A VanVeldhuisen, P Harrington, M Boron, M |
| description | Objective:
The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Study Design:
Prospective observational registry enrolling those who received ⩾1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.
Result:
Of 19 548 subjects enrolled, 40% were born before 32 weeks’, 48% between 32 and 35 weeks’ and 12% after 35 weeks’ gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age 2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
Conclusion:
Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates. |
| doi_str_mv | 10.1038/jp.2008.28 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_755131529</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A186517273</galeid><sourcerecordid>A186517273</sourcerecordid><originalsourceid>FETCH-LOGICAL-c595t-18bd328d56a129f8cf35d1ea0fac90ee15baee0bf42273700c6bbda2217a8e723</originalsourceid><addsrcrecordid>eNp90t1r1EAQAPAgij2rL_4BsihUUHLuRza78a2U-gGFFtHnZZNM7vZIsnE_Dq5_fTe9o7WiJQ-Bmd_M7rCTZa8JXhLM5KfNtKQYyyWVT7IFKUSZc16wp9kCi4LlkhXlUfbC-w3Gc1I8z46IZKXEJVtk05WDLYzB2BHZDq2tn0zQvbnWt6E2AgoWOUhhp4N1O-R3Y7MLRvdoa1z0n-dk7INHnbMDCmtAV6l-a67joGt0GUNjB_DoB6yMD273MnvW6d7Dq8P_OPv15fzn2bf84vLr97PTi7zhFQ85kXXLqGx5qQmtOtl0jLcENO50U2EAwmsNgOuuoFQwgXFT1nWrKSVCSxCUHWfv930nZ39H8EENxjfQ93oEG70SnBNGOK2SPHlUlhUVPN0lwXd_wY2NbkxTKFoWWLBCEJbU2_8qiot0ZLrwXauV7kGZsbPB6WY-V50SWXIiEkpq-Q-VvhYG09gROpPiDwpO_ihYg-7D2ts-zm_pH8IPe9g4672DTk3ODNrtFMFqXiq1mdS8VOp27jeHiWI9QHtPD1uUwMc98Ck1rsDdj_xYu1GH6OCu3WaaRQI3eYTe1w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220415227</pqid></control><display><type>article</type><title>Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Frogel, M ; Nerwen, C ; Cohen, A ; VanVeldhuisen, P ; Harrington, M ; Boron, M</creator><creatorcontrib>Frogel, M ; Nerwen, C ; Cohen, A ; VanVeldhuisen, P ; Harrington, M ; Boron, M ; Palivizumab Outcomes Registry Group ; for the Palivizumab Outcomes Registry Group</creatorcontrib><description>Objective:
The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Study Design:
Prospective observational registry enrolling those who received ⩾1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.
Result:
Of 19 548 subjects enrolled, 40% were born before 32 weeks’, 48% between 32 and 35 weeks’ and 12% after 35 weeks’ gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
Conclusion:
Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.</description><identifier>ISSN: 0743-8346</identifier><identifier>EISSN: 1476-5543</identifier><identifier>DOI: 10.1038/jp.2008.28</identifier><identifier>PMID: 18368063</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>Antibodies, Monoclonal - therapeutic use ; Antibodies, Monoclonal, Humanized ; Antiviral Agents - therapeutic use ; Cardiovascular disease ; Cardiovascular diseases ; Children ; Children & youth ; Congenital diseases ; Coronary artery disease ; Diagnosis ; Disease prevention ; Dosage and administration ; Drug therapy ; FDA approval ; Gestational age ; Government programs ; Health aspects ; Heart diseases ; Hospitalization ; Humans ; Infant ; Infant, Newborn ; Infant, Premature ; Infants ; Infants (Newborn) ; Lung diseases ; Medicine ; Medicine & Public Health ; Mortality ; Multiple births ; Neuromuscular diseases ; original-article ; Palivizumab ; Patient outcomes ; Pediatric Surgery ; Pediatrics ; Prevention ; Prophylaxis ; Prospective Studies ; Registries ; Respiratory syncytial virus ; Respiratory syncytial virus infection ; Respiratory Syncytial Virus Infections - prevention & control ; Respiratory tract ; Respiratory tract diseases ; Risk analysis ; Risk factors ; Risk groups ; Seasons ; Siblings ; Tobacco smoke ; Viruses</subject><ispartof>Journal of Perinatology, 2008-07, Vol.28 (7), p.511-517</ispartof><rights>Springer Nature America, Inc. 2008</rights><rights>COPYRIGHT 2008 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Jul 2008</rights><rights>Nature Publishing Group 2008.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c595t-18bd328d56a129f8cf35d1ea0fac90ee15baee0bf42273700c6bbda2217a8e723</citedby><cites>FETCH-LOGICAL-c595t-18bd328d56a129f8cf35d1ea0fac90ee15baee0bf42273700c6bbda2217a8e723</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18368063$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Frogel, M</creatorcontrib><creatorcontrib>Nerwen, C</creatorcontrib><creatorcontrib>Cohen, A</creatorcontrib><creatorcontrib>VanVeldhuisen, P</creatorcontrib><creatorcontrib>Harrington, M</creatorcontrib><creatorcontrib>Boron, M</creatorcontrib><creatorcontrib>Palivizumab Outcomes Registry Group</creatorcontrib><creatorcontrib>for the Palivizumab Outcomes Registry Group</creatorcontrib><title>Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry</title><title>Journal of Perinatology</title><addtitle>J Perinatol</addtitle><addtitle>J Perinatol</addtitle><description>Objective:
The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Study Design:
Prospective observational registry enrolling those who received ⩾1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.
Result:
Of 19 548 subjects enrolled, 40% were born before 32 weeks’, 48% between 32 and 35 weeks’ and 12% after 35 weeks’ gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
Conclusion:
Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.</description><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Children</subject><subject>Children & youth</subject><subject>Congenital diseases</subject><subject>Coronary artery disease</subject><subject>Diagnosis</subject><subject>Disease prevention</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>FDA approval</subject><subject>Gestational age</subject><subject>Government programs</subject><subject>Health aspects</subject><subject>Heart diseases</subject><subject>Hospitalization</subject><subject>Humans</subject><subject>Infant</subject><subject>Infant, Newborn</subject><subject>Infant, Premature</subject><subject>Infants</subject><subject>Infants (Newborn)</subject><subject>Lung diseases</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Mortality</subject><subject>Multiple births</subject><subject>Neuromuscular diseases</subject><subject>original-article</subject><subject>Palivizumab</subject><subject>Patient outcomes</subject><subject>Pediatric Surgery</subject><subject>Pediatrics</subject><subject>Prevention</subject><subject>Prophylaxis</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Respiratory syncytial virus</subject><subject>Respiratory syncytial virus infection</subject><subject>Respiratory Syncytial Virus Infections - prevention & control</subject><subject>Respiratory tract</subject><subject>Respiratory tract diseases</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Risk groups</subject><subject>Seasons</subject><subject>Siblings</subject><subject>Tobacco smoke</subject><subject>Viruses</subject><issn>0743-8346</issn><issn>1476-5543</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp90t1r1EAQAPAgij2rL_4BsihUUHLuRza78a2U-gGFFtHnZZNM7vZIsnE_Dq5_fTe9o7WiJQ-Bmd_M7rCTZa8JXhLM5KfNtKQYyyWVT7IFKUSZc16wp9kCi4LlkhXlUfbC-w3Gc1I8z46IZKXEJVtk05WDLYzB2BHZDq2tn0zQvbnWt6E2AgoWOUhhp4N1O-R3Y7MLRvdoa1z0n-dk7INHnbMDCmtAV6l-a67joGt0GUNjB_DoB6yMD273MnvW6d7Dq8P_OPv15fzn2bf84vLr97PTi7zhFQ85kXXLqGx5qQmtOtl0jLcENO50U2EAwmsNgOuuoFQwgXFT1nWrKSVCSxCUHWfv930nZ39H8EENxjfQ93oEG70SnBNGOK2SPHlUlhUVPN0lwXd_wY2NbkxTKFoWWLBCEJbU2_8qiot0ZLrwXauV7kGZsbPB6WY-V50SWXIiEkpq-Q-VvhYG09gROpPiDwpO_ihYg-7D2ts-zm_pH8IPe9g4672DTk3ODNrtFMFqXiq1mdS8VOp27jeHiWI9QHtPD1uUwMc98Ck1rsDdj_xYu1GH6OCu3WaaRQI3eYTe1w</recordid><startdate>20080701</startdate><enddate>20080701</enddate><creator>Frogel, M</creator><creator>Nerwen, C</creator><creator>Cohen, A</creator><creator>VanVeldhuisen, P</creator><creator>Harrington, M</creator><creator>Boron, M</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7RV</scope><scope>7T5</scope><scope>7T7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope></search><sort><creationdate>20080701</creationdate><title>Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry</title><author>Frogel, M ; Nerwen, C ; Cohen, A ; VanVeldhuisen, P ; Harrington, M ; Boron, M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c595t-18bd328d56a129f8cf35d1ea0fac90ee15baee0bf42273700c6bbda2217a8e723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Children</topic><topic>Children & youth</topic><topic>Congenital diseases</topic><topic>Coronary artery disease</topic><topic>Diagnosis</topic><topic>Disease prevention</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>FDA approval</topic><topic>Gestational age</topic><topic>Government programs</topic><topic>Health aspects</topic><topic>Heart diseases</topic><topic>Hospitalization</topic><topic>Humans</topic><topic>Infant</topic><topic>Infant, Newborn</topic><topic>Infant, Premature</topic><topic>Infants</topic><topic>Infants (Newborn)</topic><topic>Lung diseases</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Mortality</topic><topic>Multiple births</topic><topic>Neuromuscular diseases</topic><topic>original-article</topic><topic>Palivizumab</topic><topic>Patient outcomes</topic><topic>Pediatric Surgery</topic><topic>Pediatrics</topic><topic>Prevention</topic><topic>Prophylaxis</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Respiratory syncytial virus</topic><topic>Respiratory syncytial virus infection</topic><topic>Respiratory Syncytial Virus Infections - prevention & control</topic><topic>Respiratory tract</topic><topic>Respiratory tract diseases</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Risk groups</topic><topic>Seasons</topic><topic>Siblings</topic><topic>Tobacco smoke</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Frogel, M</creatorcontrib><creatorcontrib>Nerwen, C</creatorcontrib><creatorcontrib>Cohen, A</creatorcontrib><creatorcontrib>VanVeldhuisen, P</creatorcontrib><creatorcontrib>Harrington, M</creatorcontrib><creatorcontrib>Boron, M</creatorcontrib><creatorcontrib>Palivizumab Outcomes Registry Group</creatorcontrib><creatorcontrib>for the Palivizumab Outcomes Registry Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Perinatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Frogel, M</au><au>Nerwen, C</au><au>Cohen, A</au><au>VanVeldhuisen, P</au><au>Harrington, M</au><au>Boron, M</au><aucorp>Palivizumab Outcomes Registry Group</aucorp><aucorp>for the Palivizumab Outcomes Registry Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry</atitle><jtitle>Journal of Perinatology</jtitle><stitle>J Perinatol</stitle><addtitle>J Perinatol</addtitle><date>2008-07-01</date><risdate>2008</risdate><volume>28</volume><issue>7</issue><spage>511</spage><epage>517</epage><pages>511-517</pages><issn>0743-8346</issn><eissn>1476-5543</eissn><abstract>Objective:
The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness.
Study Design:
Prospective observational registry enrolling those who received ⩾1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites.
Result:
Of 19 548 subjects enrolled, 40% were born before 32 weeks’, 48% between 32 and 35 weeks’ and 12% after 35 weeks’ gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates.
Conclusion:
Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>18368063</pmid><doi>10.1038/jp.2008.28</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0743-8346 |
| ispartof | Journal of Perinatology, 2008-07, Vol.28 (7), p.511-517 |
| issn | 0743-8346 1476-5543 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_755131529 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents - therapeutic use Cardiovascular disease Cardiovascular diseases Children Children & youth Congenital diseases Coronary artery disease Diagnosis Disease prevention Dosage and administration Drug therapy FDA approval Gestational age Government programs Health aspects Heart diseases Hospitalization Humans Infant Infant, Newborn Infant, Premature Infants Infants (Newborn) Lung diseases Medicine Medicine & Public Health Mortality Multiple births Neuromuscular diseases original-article Palivizumab Patient outcomes Pediatric Surgery Pediatrics Prevention Prophylaxis Prospective Studies Registries Respiratory syncytial virus Respiratory syncytial virus infection Respiratory Syncytial Virus Infections - prevention & control Respiratory tract Respiratory tract diseases Risk analysis Risk factors Risk groups Seasons Siblings Tobacco smoke Viruses |
| title | Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T00%3A48%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prevention%20of%20hospitalization%20due%20to%20respiratory%20syncytial%20virus:%20results%20from%20the%20Palivizumab%20Outcomes%20Registry&rft.jtitle=Journal%20of%20Perinatology&rft.au=Frogel,%20M&rft.aucorp=Palivizumab%20Outcomes%20Registry%20Group&rft.date=2008-07-01&rft.volume=28&rft.issue=7&rft.spage=511&rft.epage=517&rft.pages=511-517&rft.issn=0743-8346&rft.eissn=1476-5543&rft_id=info:doi/10.1038/jp.2008.28&rft_dat=%3Cgale_proqu%3EA186517273%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220415227&rft_id=info:pmid/18368063&rft_galeid=A186517273&rfr_iscdi=true |